Works by Ha, Kyoung Hwa

Results: 61
    1
    2
    3
    4

    Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 75, doi. 10.1111/dom.14189
    By:
    • Birkeland, Kåre I.;
    • Bodegard, Johan;
    • Banerjee, Amitava;
    • Kim, Dae Jung;
    • Norhammar, Anna;
    • Eriksson, Jan W.;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Ha, Kyoung Hwa;
    • Kossack, Nils;
    • Mamza, Jil Billy;
    • Zhang, Ruiqi;
    • Yajima, Toshitaka;
    • Komuro, Issei;
    • Kadowaki, Takashi
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study.

    Published in:
    Journal of Diabetes Investigation, 2023, v. 14, n. 3, p. 417, doi. 10.1111/jdi.13959
    By:
    • Kim, Dae Jung;
    • Sheu, Wayne H‐H;
    • Chung, Wook‐Jin;
    • Yabe, Daisuke;
    • Ha, Kyoung Hwa;
    • Nangaku, Masaomi;
    • Tan, Elise Chia‐Hui;
    • Node, Koichi;
    • Yasui, Atsutaka;
    • Lei, Weiyu;
    • Lee, Sunwoo;
    • Saarelainen, Laura;
    • Deruaz‐Luyet, Anouk;
    • Kyaw, Moe H;
    • Seino, Yutaka
    Publication type:
    Article
    32
    33

    Healthcare resource utilization in patients treated with empagliflozin in East Asia.

    Published in:
    Journal of Diabetes Investigation, 2022, v. 13, n. 5, p. 810, doi. 10.1111/jdi.13728
    By:
    • Sheu, Wayne H‐H;
    • Seino, Yutaka;
    • Tan, Elise Chia‐Hui;
    • Yabe, Daisuke;
    • Ha, Kyoung Hwa;
    • Nangaku, Masaomi;
    • Chung, Wook‐Jin;
    • Node, Koichi;
    • Yasui, Atsutaka;
    • Lei, Wei‐Yu;
    • Lee, Sunwoo;
    • Ustyugova, Anastasia;
    • Klement, Riho;
    • Deruaz‐Luyet, Anouk;
    • Kyaw, Moe H;
    • Kim, Dae Jung
    Publication type:
    Article
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45

    Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.

    Published in:
    Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01963-9
    By:
    • Vistisen, Dorte;
    • Carstensen, Bendix;
    • Elisabetta, Patorno;
    • Lanzinger, Stefanie;
    • Tan, Elise Chia-Hui;
    • Yabe, Daisuke;
    • Kim, Dae Jung;
    • Sheu, Wayne H.-H.;
    • Melzer-Cohen, Cheli;
    • Holl, Reinhard W.;
    • Núñez, Júlio;
    • Ha, Kyoung Hwa;
    • Halvorsen, Sigrun;
    • Langslet, Gisle;
    • Karasik, Avraham;
    • Nyström, Thomas;
    • Niskanen, Leo;
    • Guleria, Sonia;
    • Klement, Riho;
    • Carrasco, Marc
    Publication type:
    Article
    46
    47
    48

    Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study.

    Published in:
    Endocrinology, Diabetes & Metabolism, 2021, v. 4, n. 1, p. 1, doi. 10.1002/edm2.183
    By:
    • Seino, Yutaka;
    • Kim, Dae Jung;
    • Yabe, Daisuke;
    • Tan, Elise Chia‐Hui;
    • Chung, Wook‐Jin;
    • Ha, Kyoung Hwa;
    • Nangaku, Masaomi;
    • Node, Koichi;
    • Klement, Riho;
    • Yasui, Atsutaka;
    • Lei, Wei‐Yu;
    • Lee, Sunwoo;
    • Kyaw, Moe H.;
    • Deruaz‐Luyet, Anouk;
    • Brodovicz, Kimberly G.;
    • H.‐H. Sheu, Wayne
    Publication type:
    Article
    49
    50